Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus ZEGERID.
ESOMEPRAZOLE MAGNESIUM vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of gastric parietal cells.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
20-40 mg orally once daily; for erosive esophagitis, 40 mg once daily for 4-8 weeks. IV: 20-40 mg once daily over 10-30 minutes.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals, but may be prolonged to 2–3 hours in poor metabolizers (CYP2C19) or patients with hepatic impairment. The effect on gastric acid secretion persists for 24 hours due to irreversible binding to proton pumps.
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (about 20%) eliminated in feces via biliary excretion. Less than 1% is excreted unchanged in urine.
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor